Triple-Negative Breast Cancer trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Triple-Negative Breast Cancer. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month6 studies across 6 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| NRIX | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | 2026-08-31 | in 11 d | 2025-09-09 |
September 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PCSA | Processa Pharmaceuticals | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692Evaluation of Objective Response Rate (ORR) | Phase 2 | Recruiting | Sep 2026 | ≤ 41 d | 2025-06-19 |
November 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| EXEL | Exelixis | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | 2026-11-23 | in 95 d | 2026-06-22 |
December 2026 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| CMPX | Compass Therapeutics | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-28 |
| MNPR | Monopar Therapeutics | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Dec 2026 | ≤ 133 d | 2025-05-21 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| 4568.T | Daiichi Sankyo Co., Ltd. | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385Number of participants with dose-limiting toxicities | Phase 1 | Active, not recruiting | 2027-01-01 | in 134 d | 2025-10-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Triple-Negative Breast Cancer
most recently updated first109 studies match. Showing the first 100 of 109 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BOLD | Boundless Bio, Inc. | $65M | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsNCT05827614Frequency and severity of treatment emergent adverse events (TEAEs) of BBI-355 as a single agent and in combination with each of the following agents: erlotinib, futibatinib, or BBI-825 | Phase 1 | Terminatedsponsor's stated reason: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal. | Drug: BBI-355, Erlotinib, Futibatinib, BBI-825 | Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer | 85 | 2023-03-24 | 2026-03-17actual | — | 2026-08-19 |
| AZN | AstraZeneca | — | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid TumorsNCT07115043Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion) | Phase 1/2 | Recruiting | Drug: AZD6750, rilvegostomig | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma | 120 | 2025-07-29 | 2029-10-02 | in 1,139 d | 2026-08-19 |
| CNTX | Context Therapeutics Inc. | $49M | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122Phase 1a: Incidence of Dose Limiting Toxicities (DLTs) | Phase 1 | Recruiting | Drug: CT-202 | Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Urothelial Cancer | 162 | Sep 2026 | Jan 2030 | ≤ 1,260 d | 2026-08-18 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsNCT04895709Incidence of adverse events (AEs) | Phase 1/2 | Recruiting | Drug: BMS-986340, BMS-936558-01, Docetaxel, Pumitamig | Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms | 1,109 | 2021-05-27 | 2031-08-31 | in 1,837 d | 2026-08-17 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | 2023-07-06 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| RADX | Radiopharm Theranostics, Ltd | — | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.NCT07272642To assess the safety and tolerability of a single dose of LNTH-2403 | Phase 1 | Not yet recruiting | Drug: LNTH-2403 | Imaging, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC) | 16 | 2026-10-30 | 2027-08-30 | in 375 d | 2026-08-12 |
| PMVP | PMV Pharmaceuticals, Inc | $66M | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750Phase 1 Monotherapy (Dose Escalation): Determine the number and type of adverse events to characterize the safety of rezatapopt | Phase 1/2 | Recruiting | Drug: rezatapopt, pembrolizumab | Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer | 300 | 2020-10-29 | 2026-08-15 | — | 2026-08-10 |
| IOVA | Iovance Biotherapeutics, Inc. | $3.2B | A Study of IOV-5001 in Adults With Advanced Solid TumorsNCT07743723Phase 1: Safety Assessment | Phase 1/2 | Not yet recruiting | Biological: IOV-5001 | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor | 106 | Aug 2026 | Mar 2034 | ≤ 2,780 d | 2026-08-06 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid TumorsNCT06465069Phase 1a: To determine the recommended phase 2 dose (RP2D) optimal dose(s) of LY4052031 | Phase 1 | Recruiting | Drug: LY4052031 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 420 | 2024-07-01 | May 2027 | ≤ 284 d | 2026-08-05 |
| AZN | AstraZeneca | — | A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerNCT03742102results2026-02-02Dose Limiting Toxicity (DLT) Events | Phase 1/2 | Active, not recruiting | Drug: Durvalumab, Capivasertib, Oleclumab, Paclitaxel, Trastuzumab deruxtecan, Datopotamab deruxtecan | Triple Negative Breast Neoplasms | 243 | 2018-12-21 | 2024-11-29actual | — | 2026-08-04 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400NCT06084481Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-400, Itraconazole (ITZ), Bevacizumab | Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Cancer, Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer, Head and Neck Squamous-Cell Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer | 302 | 2023-11-09 | Sep 2027 | ≤ 406 d | 2026-08-04 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced CancersNCT05891171Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Active, not recruiting | Drug: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin | Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC) | 40 | 2023-10-13 | Sep 2027 | ≤ 406 d | 2026-07-30 |
| CMPX | Compass Therapeutics | $430M | A Phase 1 of CTX-8371 in Patients With Advanced MalignanciesNCT06150664Cohort 1: Evaluate the safety and tolerability of escalating doses of CTX-8371 | Phase 1 | Recruiting | Drug: CTX-8371 | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Malignant Melanoma | 85 | 2024-03-19 | Dec 2026 | ≤ 133 d | 2026-07-28 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsNCT05208762Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: PF-08046054, pembrolizumab | Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma | 714 | 2022-10-25 | 2028-01-05 | in 503 d | 2026-07-22 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsNCT06157892Number of participants with dose limiting toxicities (DLTs) in dose escalation phase | Phase 2 | Active, not recruiting | Drug: disitamab vedotin, tucatinib | Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer | 54 | 2024-05-20 | 2029-07-28 | in 1,073 d | 2026-07-22 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT) | Phase 1 | Recruiting | Drug: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab | Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Triple Negative Breast Cancer | 260 | 2025-12-23 | 2029-04-14 | in 968 d | 2026-07-22 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)NCT05633654Invasive Disease-free Survival (iDFS) | Phase 3 | Recruiting | Drug: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine | Triple Negative Breast Cancer | 1,514 | 2022-12-12 | Jun 2027 | ≤ 314 d | 2026-07-15 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid TumorsNCT05101096Phase 1: Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs) Defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 | Phase 1/2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer, HR+/HER2- Metastatic Breast Cancer, Metastatic Urothelial Cancer | 135 | 2021-10-20 | May 2027 | ≤ 284 d | 2026-07-10 |
| AKTS | Aktis Oncology, Inc. | — | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid TumorsNCT07020117Part 1: Number of Patients with Dose-Limiting Toxicities | Phase 1 | Recruiting | Drug: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer, Cervical Adenocarcinoma, Colorectal Adenocarcinoma, Head and Neck Cancer | 150 | 2025-08-22 | Dec 2027 | ≤ 498 d | 2026-07-10 |
| AZN | AstraZeneca | — | To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.NCT03330847results2022-03-22Progression-free Survival Per Stratum (BICR) | Phase 2 | Active, not recruiting | Drug: Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). | Metastatic Triple Negative Breast Cancer | 273 | 2018-03-07 | 2020-11-13actual | — | 2026-07-02 |
| AZN | AstraZeneca | — | A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)NCT05460273results2025-06-13Confirmed Objective Response Rate(ORR) Assessed by Independent Central Review(ICR) | Phase 1/2 | Active, not recruiting | Drug: Datopotamab Deruxtecan (Dato-DXd) | Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer | 119 | 2022-07-11 | 2023-11-07actual | — | 2026-07-02 |
| BNTX | BioNTech SE | — | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyNCT06449222Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment emergent serious adverse events (SAEs) | Phase 2 | Active, not recruiting | Drug: BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose | Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers | 83 | 2024-08-26 | Aug 2028 | ≤ 742 d | 2026-06-30 |
| ABBV | AbbVie | $457.5B | Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanNCT05005403Number of Participants with Adverse Events (AE) | Phase 1 | Recruiting | Drug: Azirkitug, Budigalimab, Bevacizumab, Telisotuzumab Adizutecan | Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Micro Satellite Stable Colorectal Cancer, Gastric/Esophageal Cancer, High-Grade Serous Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer | 694 | 2021-11-01 | Jul 2027 | ≤ 345 d | 2026-06-23 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4175408 in Participants With Advanced CancerNCT07046923Phase 1a-Number of Participants with Dose Limiting Toxicities of LY4175408 | Phase 1 | Recruiting | Drug: LY4175408, Pembrolizumab, Carboplatin, Cisplatin | Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms, Neoplasm Metastasis, Triple Negative Breast Cancer | 240 | 2025-07-28 | Jul 2030 | ≤ 1,441 d | 2026-06-23 |
| TELO | Telomir Pharmaceuticals, Inc. | $74M | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)NCT07581314Phase I: Incidence of Serious Adverse Events (SAEs) and incidence and severity of Treatment-Emergent AEs (TEAEs) | Phase 1/2 | Not yet recruiting | Drug: Zn-Telomir | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 76 | Oct 2026 | May 2027 | ≤ 284 d | 2026-06-23 |
| EXEL | Exelixis | $13.2B | Study of XB010 in Subjects With Solid TumorsNCT06545331Dose-Escalation Stage: Maximum tolerated dose (MTD) and/or Recommended dose(s) for Expansion [RDE(s)] for XB010 | Phase 1 | Recruiting | Drug: XB010, Pembrolizumab | Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC) | 396 | 2024-08-06 | 2026-11-23 | in 95 d | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4170156 in Participants With Selected Advanced Solid TumorsNCT06400472Phase 1a: To determine the recommended phase 2 dose (RP2D) of LY4170156 | Phase 1 | Recruiting | Drug: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab | Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms | 495 | 2024-05-20 | Feb 2027 | ≤ 192 d | 2026-06-18 |
| IDYA | IDEAYA Biosciences | $3.7B | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808Safety and tolerability of IDE034 in Part 1 dose escalation | Phase 1 | Recruiting | Drug: IDE034 | Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer | 150 | 2026-02-24 | 2027-07-30 | in 344 d | 2026-06-18 |
| 4568.T | Daiichi Sankyo | $31.7B | Patterns of Care and Outcomes in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerNCT07092254observationalTreatment sequencing before the diagnosis of advanced, metastatic TNBC (i.e., all treatments received for early TNBC if initially diagnosed with earlier-stage disease) | — | Active, not recruiting | Drug: No drug | Triple Negative Breast Cancer | 760 | 2025-09-01 | 2025-11-28actual | — | 2026-06-17 |
| TEM | Tempus AI | $8.6B | Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesNCT07211178observationalInvasive Disease-Free Survival (iDFS) stratified by MRD status during neoadjuvant, post-surgery landmark, post definitive treatment (surveillance), and long-term follow-up | — | Recruiting | Other: There are no interventions in this observational study. | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer | 900 | 2025-10-27 | Dec 2032 | ≤ 2,325 d | 2026-06-12 |
| RXRX | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | $1.7B | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | 2026-04-13 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| REGN | Regeneron Pharmaceuticals | $76.1B | A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerNCT04916002results2025-12-05Objective Response Rate (ORR) | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision related to study drug supply | Drug: vidutolimod, cemiplimab | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer, Oropharynx Squamous Cell Carcinoma | 77 | 2021-11-30 | 2024-10-31actual | — | 2026-06-09 |
| JANX | Janux Therapeutics | $1.0B | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor MalignanciesNCT05783622Incidence of Dose Limiting Toxicities (DLT) | Phase 1 | Active, not recruiting | Drug: JANX008 | Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma, Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple-negative Breast Cancer | 130 | 2023-04-19 | 2026-07-31 | — | 2026-06-01 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsNCT06238479Phase 1a: To determine the recommended dose of LY4101174 | Phase 1 | Active, not recruiting | Drug: LY4101174 | Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Renal Pelvis Cancer, Bladder Cancer | 490 | 2024-03-05 | Mar 2027 | ≤ 223 d | 2026-05-22 |
| LTRN | Lantern Pharma Inc. | $32M | Study of LP-184 in Patients With Advanced Solid TumorsNCT05933265To evaluate the safety and tolerability of LP-184 assessed by the incidence and severity of all adverse events graded by CTCAE v5.0 | Phase 1/2 | Active, not recruiting | Drug: LP-184, Olaparib, Nivolumab & Ipilimumab | Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation | 64 | 2023-06-09 | 2026-07-28 | — | 2026-05-04 |
| CYDY | CytoDyn, Inc. | $269M | An Open-Label, Multicenter, Non-Randomized Expanded Access Protocol (EAP) Designed to Provide Leronlimab to Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer (mTNBC)NCT07536815expanded access | — | Available | Drug: leronlimab (PRO 140) | TNBC, TNBC - Triple-Negative Breast Cancer, TNBC, Triple Negative Breast Cancer | — | — | — | — | 2026-04-27 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382299Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin | Triple Negative Breast Cancer, PD-L1 Negative | 623 | 2022-07-20 | Jul 2028 | ≤ 711 d | 2026-04-06 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871Recommended dose(s) of 177Lu-BetaBart for future exploration (phase 1) | Phase 1/2 | Recruiting | Drug: 177Lu-BetaBart | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) | 61 | 2026-02-23 | Dec 2027 | ≤ 498 d | 2026-03-27 |
| RADX | Radiopharm Theranostics, Ltd | — | 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsNCT06305962Time Activity Curves (TACs) | Early Phase 1 | Recruiting | Drug: 177Lu-RAD204 | PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer, Cutaneous Melanoma, HNSCC, Endometrial Cancer, Mmr Deficiency, MSI-High | 30 | 2024-06-03 | Dec 2027 | ≤ 498 d | 2026-02-19 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior TreatmentsNCT04454437Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v 1.1) By Independent Review Committee (IRC) | Phase 2 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy | Metastatic Triple-negative Breast Cancer | 80 | 2020-10-23 | 2021-08-06actual | — | 2026-02-02 |
| GILD | Gilead Sciences | $177.9B | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast CancerNCT06926920Phase 1: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: Sacituzumab Govitecan-hziy (SG) | Triple Negative Breast Cancer | 100 | 2025-04-30 | Jun 2028 | ≤ 680 d | 2026-01-30 |
| PFE | Seagen, a wholly owned subsidiary of Pfizer | $155.3B | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsNCT05194072Number of participants with adverse events (AEs) | Phase 1 | Terminatedsponsor's stated reason: The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns | Drug: Felmetatug Vedotin, Pembrolizumab | Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma | 250 | 2022-01-12 | 2025-05-14actual | — | 2026-01-09 |
| AZN | AstraZeneca | — | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCNCT03997123Overall Survival (OS) | Phase 3 | Active, not recruiting | Drug: Capivasertib, Paclitaxel, Placebo | Triple Negative Breast Neoplasms | 923 | 2019-06-25 | 2026-03-16 | — | 2025-12-22 |
| TNG.PA | Transgene | $231M | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid TumorsNCT04725331Phase I: Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0) | Phase 1/2 | Terminatedsponsor's stated reason: Sponsor decision following completion of Phase I part not driven by safety reason | Biological: BT-001 · Drug: Pembrolizumab [KEYTRUDA®] | Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer | 31 | 2021-02-25 | 2025-10-22actual | — | 2025-11-21 |
| BOLT | Bolt Biotherapeutics, Inc. | $6M | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesNCT06052852Incidence of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) graded according to CTCAE v5.0 | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BDC-3042, Cemiplimab | Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Head and Neck Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Melanoma | 17 | 2023-10-11 | 2025-08-01actual | — | 2025-11-17 |
| NUVB | Nuvation Bio Inc. | $2.4B | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNCT05252390Phase 1 Monotherapy Dose Escalation: Safety and tolerability of NUV-868 to determine the recommended Phase 2 dose (RP2D) | Phase 1 | Terminatedsponsor's stated reason: The Sponsor has achieved its objectives. | Drug: NUV-868, Olaparib, Enzalutamide | Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor | 82 | 2022-03-29 | 2024-07-15actual | — | 2025-11-06 |
| GILD | Gilead Sciences | $177.9B | Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast CancerNCT04958785results2025-10-03Safety Run-in Cohorts 1 and 2: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs) | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision to terminate study. | Drug: Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy | Triple-Negative Breast Cancer | 92 | 2021-12-14 | 2024-10-08actual | — | 2025-11-04 |
| NANO.PA | Nanobiotix | — | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339[Dose Escalation Part]: Determination of the Recommended Dose | Phase 1 | Active, not recruiting | Drug: NBTXR3, Nivolumab, Pembrolizumab · Radiation: SABR | Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver, Squamous Cell Carcinoma of Head and Neck, Metastasis From Malignant Tumor of Cervix, Metastatic Renal Cell Carcinoma, Metastasis From Malignant Melanoma of Skin (Disorder), Metastatic Triple-Negative Breast Carcinoma, Metastatic NSCLC, Metastasis From Malignant Tumor of Bladder (Disorder) | 145 | 2019-01-16 | 2027-04-30 | in 253 d | 2025-10-24 |
| 4568.T | Daiichi Sankyo Co., Ltd. | $31.7B | First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)NCT03401385Number of participants with dose-limiting toxicities | Phase 1 | Active, not recruiting | Drug: Datopotamab Deruxtecan (Dato-DXd), Steroid Containing Mouthwash · Other: Non-Steroid Containing Mouthwash | Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, Non-small Cell Lung Cancer | 890 | 2018-01-31 | 2027-01-01 | in 134 d | 2025-10-21 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerNCT05382286Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | Phase 3 | Active, not recruiting | Drug: Sacituzumab Govitecan-hziy, Pembrolizumab, Paclitaxel, nab-Paclitaxel, Gemcitabine, Carboplatin | Triple Negative Breast Cancer, PD-L1 Positive | 443 | 2022-07-25 | Feb 2027 | ≤ 192 d | 2025-09-18 |
| CYDY | CytoDyn, Inc. | $269M | Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBCNCT03838367results2025-09-09Phase I: Maximum Tolerated Dose (MTD) of Leronlimab (PRO 140) When Combined With Carboplatin AUC5 | Phase 1/2 | Terminatedsponsor's stated reason: Study terminated prematurely due to business reasons. Participants are no longer examined or receiving intervention. | Drug: 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab, AUC 5 Carboplatin, Maximum Tolerated Dose (MTD) of leronlimab | Triple Negative Breast Neoplasms | 10 | 2019-04-22 | 2022-07-15actual | — | 2025-09-09 |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | A Study of NX-1607 in Adults With Advanced MalignanciesNCT05107674Incidence of treatment-emergent adverse events (TEAEs), including Grade ≥ 3 TEAEs, treatment-emergent serious adverse events (SAEs), TEAEs leading to study drug discontinuation, and deaths due to TEAEs | Phase 1 | Recruiting | Drug: NX-1607, Paclitaxel | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma | 345 | 2021-09-29 | 2026-08-31 | in 11 d | 2025-09-09 |
| EXEL | Exelixis | $13.2B | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960Dose Escalation: MTD/Recommended Dose | Phase 1 | Active, not recruiting | Drug: cabozantinib, atezolizumab, cabozantinib, cabozantinib | Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer | 914 | 2017-09-05 | 2023-02-21actual | — | 2025-08-17 |
| ABBV | AbbVie | $457.5B | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsNCT03893955Dose Expansion: Objective Response Rate (ORR) | Phase 1 | Active, not recruiting | Drug: ABBV-927, ABBV-368, ABBV-181, Carboplatin, Nab-paclitaxel | Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC), Metastatic Solid Tumors | 150 | 2019-05-21 | Mar 2026 | — | 2025-08-12 |
| XNCR | Xencor, Inc. | $1.9B | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid TumorsNCT05585034Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Completed | Biological: XmAb®808, Keytruda® (pembrolizumab) | Head and Neck Squamous Cell Carcinoma, Melanoma Excluding Uveal Melanoma, Non-small Cell Lung Cancer, Squamous or Non-squamous, Urothelial Carcinoma, Renal Cell Carcinoma, Clear Cell, Castration-resistant Prostate Cancer, Ovarian Cancer, Epithelial, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer | 60 | 2022-12-14 | 2025-05-20actual | — | 2025-08-07 |
| MGNX | MacroGenics | $261M | MGC018 With or Without MGA012 in Advanced Solid TumorsNCT03729596results2025-07-31Number of Patients With Adverse Events of Vobramitamab Duocarmazine as Assessed by CTCAE v4.03 | Phase 1/2 | Terminatedsponsor's stated reason: Business decision | Biological: vobramitamab duocarmazine | Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Melanoma, Advanced Solid Tumor, Adult, Metastatic Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer | 143 | 2018-11-21 | 2023-03-18actual | — | 2025-07-31 |
| CYDY | CytoDyn, Inc. | $269M | A Compassionate Use Study of Leronlimab in Breast CancerNCT04313075expanded access | — | No longer available | Drug: Leronlimab | Metastatic Triple-Negative Breast Carcinoma | — | — | — | — | 2025-07-15 |
| INCY | Incyte Corporation | $24.7B | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsNCT04580485Number of treatment-emergent adverse events (TEAE) | Phase 1 | Completed | Drug: INCB106385, INCMGA00012 | Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer, Castration Resistant Prostate Cancer, Colorectal Cancer, Gastric/ Gastroesophageal Junction, Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Squamous Carcinoma of the Anal Canal | 54 | 2021-02-03 | 2024-01-22actual | — | 2025-07-11 |
| MDNAF | Medicenna Therapeutics, Inc. | $22M | A Beta-only IL-2 ImmunoTherapY StudyNCT05086692MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE) | Phase 1/2 | Recruiting | Drug: MDNA11, Pembrolizumab (KEYTRUDA®) | Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer | 115 | 2021-08-27 | 2026-06-30 | — | 2025-07-09 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Study to Investigate LYL797 in Adults With Solid TumorsNCT05274451Evaluate incidence of dose-limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Pipeline Reprioritization | Biological: LYL797 | Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 57 | 2022-03-29 | 2024-11-27actual | — | 2025-07-01 |
| LYEL | Lyell Immunopharma, Inc. | $332M | A Biomarker Screening Protocol for Participants With Solid TumorsNCT05891197observationalTo identify participants whose tumors express biomarkers, such as ROR1, that may inform eligibility for active and future Lyell clinical trials | — | Terminatedsponsor's stated reason: Pipeline Reprioritization | — | Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer | 10 | 2023-05-19 | 2025-02-05actual | — | 2025-07-01 |
| PCSA | Processa Pharmaceuticals | $6M | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerNCT06568692Evaluation of Objective Response Rate (ORR) | Phase 2 | Recruiting | Drug: PCS6422 and capecitabine, Capecitabine | Breast Cancer, TNBC - Triple-Negative Breast Cancer, HER2-negative Breast Cancer | 90 | 2024-10-02 | Sep 2026 | ≤ 41 d | 2025-06-19 |
| MNPR | Monopar Therapeutics | $799M | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsNCT06337084To assess dosimetry and biodistribution of MNPR-101-DFO*-89Zr | Phase 1 | Recruiting | Drug: MNPR-101-DFO*-89Zr · Diagnostic test: PET/CT Diagnostic Imaging | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-05-30 | Apr 2026 | — | 2025-05-22 |
| MNPR | Monopar Therapeutics | $799M | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsNCT06617169Identify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency | Phase 1 | Recruiting | Drug: MNPR-101-PCTA-177Lu | Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer, Lung Cancer, Colorectal Cancer, Gastric Cancer, Ovarian Cancer, Pancreatic Cancer | 12 | 2024-10-08 | Dec 2026 | ≤ 133 d | 2025-05-21 |
| EXEL | Exelixis | $13.2B | Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284Dose-Escalation Stage: MTD/recommended dose for XB002 | Phase 1 | Completed | Drug: XB002, Nivolumab, Bevacizumab | Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors | 269 | 2021-06-07 | 2025-03-10actual | — | 2025-04-04 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyNCT03175666Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. | Phase 1/2 | Withdrawnsponsor's stated reason: Trial not initiated | Biological: avelumab, bevacizumab, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK · Drug: capecitabine, cisplatin, cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-paclitaxel, Lovaza · Radiation: Stereotactic Body Radiation Therapy | Triple Negative Breast Cancer | 0 | Dec 2017 | Jan 2019 | — | 2025-02-21 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineNCT03554109Pathological Complete Response Rate | Phase 2 | Withdrawnsponsor's stated reason: Trial not initiated | Drug: Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, Avelumab, Cyclophosphamide, Doxorubicin HCL, paclitaxel · Biological: ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, ALT-803, haNK | Triple Negative Breast Cancer (TNBC) | 0 | Sep 2018 | Jun 2020 | — | 2025-02-21 |
| BCAB | BioAtla, Inc. | $187M | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)NCT03504488Phase 1: Safety Profile | Phase 1/2 | Completed | Biological: CAB-ROR2-ADC, PD-1 inhibitor | Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer | 132 | 2018-06-27 | 2024-12-30actual | — | 2025-01-15 |
| PSNL | Personalis Inc. | $1.5B | CtDNA Based MRD Testing for NAC Monitoring in TNBCNCT06230185observationalEvaluate the correlation of MRD to pCR after NAC in TNBC | — | Recruiting | — | TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease | 422 | 2023-11-09 | 2025-08-30 | — | 2025-01-07 |
| SLS | Sellas Life Sciences Group | $2.6B | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced CancersNCT03761914results2024-11-19Overall Response Rate (ORR) - Best Overall Response | Phase 1/2 | Completed | Biological: galinpepimut-S, pembrolizumab, GM-CSF · Other: Montanide | Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer | 26 | 2019-09-30 | 2022-07-05actual | — | 2024-11-19 |
| AZN | AstraZeneca | — | First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursNCT04504669Maximum Tolerated dose (or optimal dose or maximum feasible dose) and RP2D of AZD8701 as monotherapy and in combination with Durvalumab assessed through evaluation of AEs and SAEs | Phase 1 | Completed | Drug: AZD8701 · Biological: Durvalumab | Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours | 60 | 2020-08-18 | 2024-10-07actual | — | 2024-11-05 |
| PFE | Pfizer | $155.3B | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBCNCT03674827results2024-08-23Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology portfolio; the study was not terminated because of safety concerns. | Biological: PF-06936308 | Non-Small Cell Lung Cancer, Triple-negative Breast Cancer | 36 | 2018-11-27 | 2021-09-27actual | — | 2024-08-23 |
| IBRX | ImmunityBio, Inc. | $8.2B | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.NCT03387085results2024-08-09Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs) | Phase 1/2 | Terminatedsponsor's stated reason: Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention | Drug: Aldoxorubicin HCl, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel · Biological: N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab · Procedure: SBRT | Triple Negative Breast Cancer | 9 | 2018-03-19 | 2020-09-11actual | — | 2024-08-09 |
| ADCT | ADC Therapeutics S.A. | $131M | Study of ADCT-301 in Patients With Selected Advanced Solid TumorsNCT03621982results2024-06-13Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs) | Phase 1 | Terminatedsponsor's stated reason: Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study. | Drug: ADCT-301 · Biological: Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer, Pancreas Cancer, Bladder Cancer, Renal Cell Carcinoma, Melanoma, Triple-negative Breast Cancer, Ovarian Cancer, Colo-rectal Cancer, Fallopian Tube Cancer | 78 | 2018-11-09 | 2022-12-14actual | — | 2024-06-13 |
| RCUS | Arcus Biosciences, Inc. | $3.8B | A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic MalignanciesNCT03719326Incidence of Adverse Events (AEs) | Phase 1 | Completed | Drug: Etrumadenant, IPI-549, Pegylated liposomal doxorubicin (PLD), nanoparticle albumin-bound paclitaxel (NP) | TNBC - Triple-Negative Breast Cancer, Ovarian Cancer | 35 | 2018-10-15 | 2021-07-01actual | — | 2024-05-24 |
| AMGN | Amgen | $229.9B | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesNCT03256344results2021-06-09Number of Participants Who Experienced a Dose-Limiting Toxicity (DLT) | Phase 1 | Completed | Biological: Talimogene Laherparepvec, Atezolizumab | Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer | 36 | 2018-03-19 | 2020-05-26actual | — | 2024-05-14 |
| EXEL | Exelixis | $13.2B | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332Dose-Escalation Stage: MTD/recommended dose for XL102 | Phase 1 | Terminatedsponsor's stated reason: Business reasons | Drug: XL102, Fulvestrant, Abiraterone, Prednisone | Neoplasm Malignant, Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer | 52 | 2021-02-10 | 2024-05-02actual | — | 2024-05-14 |
| MGNX | MacroGenics | $261M | A Study of MGD013 in Patients With Unresectable or Metastatic NeoplasmsNCT03219268Number of participants with Treatment-Emergent Adverse Events (TEAE) as assessed by CTCAE v4.03 (tebotelimab monotherapy) | Phase 1 | Completed | Biological: tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg, tebotelimab 30 mg, tebotelimab 120 mg, tebotelimab 300 mg, tebotelimab 400 mg, tebotelimab 600 mg, tebotelimab 800 mg, tebotelimab 1200 mg, margetuximab | Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Cholangiocarcinoma, Cervical Cancer, TNBC - Triple-Negative Breast Cancer | 277 | 2017-08-18 | 2023-02-08actual | — | 2023-12-21 |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersNCT03454451Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab. | Phase 1 | Completed | Drug: CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab | Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma | 117 | 2018-04-25 | 2022-12-28actual | — | 2023-12-21 |
| AZN | AstraZeneca | — | Study of Tremelimumab in Patients With Advanced Solid TumorsNCT02527434results2019-03-05Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase | Phase 2 | Completed | Biological: Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy | Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma | 64 | 2015-11-02 | 2018-02-17actual | — | 2023-11-15 |
| TPST | Tempest Therapeutics | $16M | TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced CancersNCT03829436Incidence of dose limiting toxicities (DLTs) of TPST-1120 as a single agent and in combination with nivolumab. | Phase 1 | Completed | Drug: Part 1 TPST-1120, Part 2 TPST-1120 + nivolumab, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab | Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma | 38 | 2019-03-20 | 2022-09-07actual | — | 2023-07-03 |
| 4523.T | Eisai Limited | $8.7B | An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid TumorsNCT01618136Phase 1 To determine the maximum tolerated dose of E7449 as a single agent | Phase 1/2 | Completed | Drug: E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel | Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma, B-cell Malignancy, Low-grade | 41 | Jan 2012 | Jul 2015actual | — | 2023-06-18 |
| XNCR | Xencor, Inc. | $1.9B | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid TumorsNCT03849469Safety and tolerability profile of XmAb22841 assessed by rates of treatment-related adverse events (AEs), graded by CTCAE v4.03. | Phase 1 | Completed | Biological: XmAb®22841, Pembrolizumab (Keytruda®) | Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma | 78 | 2019-05-29 | 2023-02-16actual | — | 2023-03-30 |
| NKTR | Nektar Therapeutics | $2.5B | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsNCT02983045results2023-03-13Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window | Phase 1/2 | Completed | Drug: Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab | Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer | 557 | 2016-12-19 | 2022-04-28actual | — | 2023-03-13 |
| NKTR | Nektar Therapeutics | $2.5B | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesNCT03435640results2023-03-08Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | Phase 1/2 | Terminatedsponsor's stated reason: Based on the overall results from the Phase 1 part of the study the sponsor decided to end the study. The decision was not due to safety reasons. | Drug: NKTR-262, bempegaldesleukin, nivolumab | Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Colorectal Cancer, Sarcoma | 64 | 2018-03-15 | 2022-05-09actual | — | 2023-03-08 |
| GOSS | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | $70M | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaNCT04060342Phase 1 Dose Escalation - Regimens A, B,and C: Incidence of dose limiting toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Drug: GB1275, nab-paclitaxel and gemcitabine, pembrolizumab | Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma | 61 | 2019-08-13 | 2022-04-11actual | — | 2022-08-18 |
| ABBV | AbbVie | $457.5B | Expanded Access to VeliparibNCT03123211expanded access | — | No longer available | Drug: Veliparib | Solid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically Sound, Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Cancer, Patients Requiring Veliparib Suspension Formulation | — | — | — | — | 2022-05-24 |
| INCY | Incyte Corporation | $24.7B | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected CancersNCT02178722results2019-12-19Phase 1: Percentage of Participants With Treatment-Emergent Adverse Events (TEAE) and Serious Treatment-Emergent Adverse Events | Phase 1/2 | Completed | Drug: MK-3475, INCB024360 | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC) | 444 | 2014-07-17 | 2018-11-26actual | — | 2022-02-14 |
| MGNX | MacroGenics | $261M | Safety Study of MGA271 in Refractory CancerNCT01391143Safety | Phase 1 | Completed | Biological: MGA271 | Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer | 179 | Jul 2011 | 2019-04-18actual | — | 2022-02-08 |
| VERU | Veru Inc. | $220M | P2 Clinical Efficacy & Safety Study of V-111 Monotherapy & Sacituzumab Govitecan-hziy/V-111 Combo Therapy for mTNBC .NCT05008510To compare the efficacy of sabizabulin monotherapy to Sacituzumab govitecan-hziy monotherapy | Phase 2 | Withdrawnsponsor's stated reason: Decided to halt and will potentially reopen in the future. | Drug: Sabizabulin, Sacituzumab Govitecan-hziy, Sabizabulin/Sacituzumab govitecan-hziy Combo | Metastatic Triple Negative Breast Cancer | 0 | 2021-12-30 | 2022-07-30 | — | 2022-02-08 |
| INCY | Incyte Corporation | $24.7B | A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesNCT03652077Number of treatment-emergent adverse events | Phase 1 | Completed | Drug: INCAGN02390 | Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency | 40 | 2018-09-24 | 2021-08-18actual | — | 2021-11-15 |
| SNY | Sanofi | — | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast CancerNCT02984683results2021-09-08Number of Participants With Investigational Medicinal Product (IMP)-Related Predefined Safety Criteria Findings | Phase 2 | Terminatedsponsor's stated reason: Study discontinued considering the limited clinical benefit combined with a higher than expected rate of known non-serious ophthalmological event. | Drug: SAR566658 (ACT14884) | Triple Negative Breast Cancer | 23 | 2017-03-23 | 2018-09-07actual | — | 2021-09-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3435151 in Participants With Solid TumorsNCT04099277results2021-08-31Number of Participants With LY3435151 Dose-Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to strategic business decision by Eli Lilly and Company. | Drug: LY3435151, Pembrolizumab | Solid Tumor, Triple-negative Breast Cancer, Gastric Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Cervical Carcinoma, High Grade Serous Ovarian Carcinoma, Hepatocellular Carcinoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma | 2 | 2019-10-28 | 2020-03-05actual | — | 2021-08-31 |
| GILD | Gilead Sciences | $177.9B | Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast CancerNCT02161679Progression Free Survival | Phase 2 | Withdrawnsponsor's stated reason: FDA asked to administratively split from IND115621- to open a new IND you need to file a protocol we only drafted it to get the IND open - never initiated | Drug: IMMU-132 infusion is administered to participants in one arm for the study, IMMU-132 plus Carboplatin infusion | Triple-negative Breast Cancer | 0 | Aug 2016 | Aug 2016actual | — | 2021-08-19 |
| GILD | Gilead Sciences | $177.9B | Expanded Access for IMMU-132NCT04320693expanded access | — | Approved for marketing | Drug: IMMU-132 | Metastatic Triple-Negative Breast Carcinoma | — | — | — | — | 2021-08-19 |
| GILD | Gilead Sciences | $177.9B | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerNCT01631552results2021-04-06Percentage of Participants Experiencing Any Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events | Phase 1/2 | Completed | Drug: Sacituzumab Govitecan-hziy (SG) | Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer | 515 | 2012-12-17 | 2019-03-01actual | — | 2021-08-12 |
| LLY | Eli Lilly and Company | $1.15T | A Study of AK-01 (LY3295668) in Solid TumorsNCT03092934results2021-07-02Phase 1: Maximum Tolerated Dose | Phase 1/2 | Completed | Drug: LY3295668 | Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms, Breast Neoplasms, Solid Tumor, Adult, Small Cell Lung Carcinoma | 13 | 2017-05-29 | 2020-04-20actual | — | 2021-07-02 |
| ABBV | AbbVie | $457.5B | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast CancerNCT02032277Pathological Complete Response (pCR). | Phase 3 | Completed | Drug: Cyclophosphamide, Placebo, Doxorubicin, Paclitaxel, Carboplatin, Veliparib, Placebo | Triple Negative Breast Cancer | 634 | 2014-04-02 | 2016-03-18actual | — | 2021-01-20 |
| AZN | AstraZeneca | — | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsNCT02658214Laboratory findings (including: clinical chemistry, hematology, and urinalysis) | Phase 1 | Completed | Drug: paclitaxel + carboplatin, carboplatin + etoposide, gemcitabine + carboplatin, nab-paclitaxel (paclitaxel-albumin) + carboplatin, oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid), nab-paclitaxel (paclitaxel-albumin) + gemcitabine, cisplatin + 5-fluorouracil (5FU) · Biological: durvalumab, tremelimumab | Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms, Triple Negative Breast Neoplasms, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Esophagogastric Junction Neoplasms, Carcinoma, Pancreatic Ductal, Esophageal Squamous Cell Carcinoma | 32 | 2016-04-28 | 2019-11-14actual | — | 2020-08-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid TumorsNCT03343613Number of Participants with Dose Limiting Toxicities (DLTs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to strategic business decision by Eli Lilly and Company. | Drug: LY3381916, LY3300054 | Solid Tumor, Non Small Cell Lung Cancer, Renal Cell Carcinoma, Triple Negative Breast Cancer | 60 | 2017-11-17 | 2020-02-07actual | — | 2020-06-09 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Triple-Negative Breast Cancer is matched — 11 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Triple Negative Breast Cancer
- Triple Negative Breast Neoplasms
- Triple Negative Breast Cancer (TNBC)
- Triple-negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Metastatic Triple Negative Breast Cancer
- Metastatic Triple-Negative Breast Carcinoma
- TNBC, Triple Negative Breast Cancer
- Metastatic Triple-negative Breast Cancer
- TNBC
- Triple-Negative Breast Cancer (TNBC)
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Triple-Negative Breast Cancer” (a text search, wider than this page)